IPA

EQS-News: FRIEDRICH VORWERK generates revenues of €373 million in 2023 with an EBITDA margin of 8.6% and expects further sales and earnings growth in 2024 with an order backlog of €1 billion

Retrieved on: 
Wednesday, April 10, 2024
Electricity, Tostedt, Annual, Annual report, Growth, IPA, Investment, Cryptocurrency

Net liquidity amounted to €42.1 million at the end of the financial year, an improvement of €14.8 million compared to the previous year.

Key Points: 
  • Net liquidity amounted to €42.1 million at the end of the financial year, an improvement of €14.8 million compared to the previous year.
  • Against this backdrop, a dividend of €0.12 per share will be proposed to the Annual General Meeting on June 3, 2024.
  • In the fourth quarter of 2023, Friedrich Vorwerk generated revenues of €98.2 million and EBITDA of €11.6 million.
  • The order backlog as at December 31, 2023 amounted to €1,001 million, more than tripling the previous year's figure of €315 million.

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, TFF, Administration, Conference, Patient, IPA, EAP, Mortality, G&A, Lung transplantation, Insurance, AAAM, Microsoft Access, Research and development, Infection, Safety, FDA, Heart, Corporation, Pharmaceutical industry

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.
  • For TFF TAC, the Company presented data showing that eight out of eight patients successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • In the fourth quarter 2023, the Company announced the appointment of three new members of its Board of Directors, including Thomas B.

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024
Principal, Annual, Fungal infection, TFF, COVID, Intubation, International Society, Part, Patient, Biomarker, IPA, Spirometry, EAP, Mortality, Lung transplantation, Microsoft Access, Potential, Safety, Kidney, Heart, Pharmaceutical industry

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

TFF Pharmaceuticals Announces Update on Clinical Programs

Retrieved on: 
Wednesday, March 20, 2024
Health, TFF, P-value, Acceleration, Partnership, Patient, IPA, EAP, KOL, Mortality, Clinical research associate, Microsoft Access, Calendar, Potential, Safety, Voriconazole, Pharmaceutical industry

FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, is announcing data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of TFF TAC, the potential to address a significant unmet need in lung transplant medicine, and substantial market opportunity, the Company has made the decision to prioritize the TFF TAC program and focus resources on the acceleration of its clinical pathway towards registration.

Key Points: 
  • “However, after a rigorous assessment of our pipeline, including the significant capital and resources required to progress both clinical development programs, we will focus our clinical development efforts and financial resources on TFF TAC.
  • In summary, for TFF TAC, eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • The Company will host a conference call on Wednesday, March 27, 2024, at 4:30 PM Eastern Time, to discuss updated clinical data for the TFF TAC and TFF VORI.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
Wednesday, March 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”

Deschutes Brewery Introduces Fresh Squeezed Non-Alcoholic IPA to the Market Alongside Black Butte Non-Alcoholic and Installs Groundbreaking Patented and Proprietary Non-Alcoholic Brewing Tech

Retrieved on: 
Tuesday, March 19, 2024
Millennials, SBT, Taste, Partnership, Coffee, IPA, Research, Deschutes Brewery, Sale, Energy drink, System, Generation Z, Restaurant, Pasteurization, Safety, CMO, Chocolate, ABV, Beer, English brewery cask units

BEND, Ore., March 19, 2024 (GLOBE NEWSWIRE) -- With over three decades of experience brewing delicious craft beers and delivering award-winning innovations, Deschutes Brewery has unveiled its next chapter of investment in the future of non-alcoholic brewing with the introduction of Fresh Squeezed Non-Alcoholic IPA. Crafted entirely in-house through a partnership with Sustainable Beverage Technologies (SBT) and utilizing the company’s patented BrewVo® technology in combination with Deschutes’ proprietary brewing methods, this groundbreaking technology allows Deschutes to create the best-tasting flavor-forward non-alcoholic beer on the market. The introduction of Fresh Squeezed Non-Alcoholic IPA comes on the heels of Deschutes’ first packaged non-alcoholic beer, Black Butte Non-Alcoholic, which quickly became the brewery’s highest rate-of-sale six-pack.

Key Points: 
  • The introduction of Fresh Squeezed Non-Alcoholic IPA comes on the heels of Deschutes’ first packaged non-alcoholic beer, Black Butte Non-Alcoholic, which quickly became the brewery’s highest rate-of-sale six-pack.
  • At Deschutes, we are all for beer and proud to make beer for all,” said Julie Galbraith, CMO of Deschutes Brewery.
  • Inspired by America’s favorite craft porter, Black Butte, Black Butte Non-Alcoholic was Deschutes’ first packaged non-alcoholic beer.
  • The original Black Butte Porter and Black Butte Non-Alcoholic both feature updated packaging artwork with illustrations by artist Sam Larson.

Terran Orbital Showcases Key Programs at 2024 Space Symposium

Retrieved on: 
Friday, April 5, 2024
Other Science, Technology, Research, Other Defense, Engineering, Contracts, Aerospace, Manufacturing, Mobile, Wireless, Defense, Military, Machinery, Satellite, Government Technology, Other Technology, Audio, Video, Telecommunications, Networks, Internet, Science, Climate change, Learning, Entrepreneurship, Nebula, SDA, IPA, Moon, Interview, Space Symposium, Booth, GEO, Multimedia, The Broadmoor, Communications satellite

Today, Terran Orbital Corporation (NYSE: LLAP ) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, announces its space-related technologies and programs for the 2024 39th Space Symposium (April 8-11, Broadmoor Hotel, Colorado Springs, CO).

Key Points: 
  • Today, Terran Orbital Corporation (NYSE: LLAP ) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, announces its space-related technologies and programs for the 2024 39th Space Symposium (April 8-11, Broadmoor Hotel, Colorado Springs, CO).
  • Schedule an interview with Marc Bell, Terran Orbital's Co-Founder, Chairman, and CEO, to learn more about Terran Orbital's vision for the future of space.
  • Schedule a meeting with our leadership team at 2024 Space Symposium April 9-11, 2024.
  • Join Terran Orbital and Advanced Space for a Happy Hour at the Space Symposium to celebrate 500+ days of the CAPSTONE mission in lunar orbit!

Anthem Blue Cross and Blue Shield Partners with Care2U and Independent Practice Association of New York, Inc. to Avoid Hospitalizations Through Advanced Care at Home Program

Retrieved on: 
Monday, March 25, 2024
Insurance, Hospitals, Telemedicine, Virtual Medicine, Professional Services, Health Insurance, Practice Management, Other Health, Managed Care, General Health, Health, RN, Elevance Health, Risk, Patient, IPA, MD, New Yorker, Blue Shield, Anatomical pathology, EKG, Hospital, Nursing

Anthem Blue Cross and Blue Shield in New York (formerly Empire BlueCross BlueShield) recently honored Care2U and Independent Practice Association of New York (IPA NY), part of Vytalize Health, with the inaugural Anthem Blue Cross and Blue Shield Innovation in Healthcare Award for the organizations’ work to improve health outcomes through its new High-Intensity Physician-Led Advanced Care at Home (HIPLACH) program.

Key Points: 
  • Anthem Blue Cross and Blue Shield in New York (formerly Empire BlueCross BlueShield) recently honored Care2U and Independent Practice Association of New York (IPA NY), part of Vytalize Health, with the inaugural Anthem Blue Cross and Blue Shield Innovation in Healthcare Award for the organizations’ work to improve health outcomes through its new High-Intensity Physician-Led Advanced Care at Home (HIPLACH) program.
  • This innovative collaboration provides state-of-the-art care in the home by a treating Care2U physician and other clinicians for members with acute conditions that would otherwise require inpatient hospitalization.
  • The program focuses on improving the quality of care, enhancing the patient experience, and lowering overall costs.
  • “IPA NY and Care2U have been the ideal partners to help us achieve our mission of improving the health of New Yorkers.

Marcus & Millichap Publishes Institutional Multifamily Market Intelligence Report

Retrieved on: 
Thursday, March 21, 2024
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, Consulting, REIT, Momentum, IPA, MMI, Marcus & Millichap, Research, Growth, Face, San Francisco Bay Area, Property management

Marcus & Millichap (NYSE:MMI) , a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today it has released its Markets with Momentum report.

Key Points: 
  • Marcus & Millichap (NYSE:MMI) , a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today it has released its Markets with Momentum report.
  • The report cites key national multifamily performance statistics from February on rent growth, lease renewals, and vacancy.
  • Highlights of the report include:
    Nationally, average monthly apartment rents have climbed $6 so far in 2024.
  • This small improvement reverses the trend of mild rent cuts seen during the last half of 2023.

$125 Million Silicon Valley Multifamily Asset Sale and Financing Brokered by Institutional Property Advisors

Retrieved on: 
Monday, March 18, 2024
Commercial Building & Real Estate, Construction & Property, Finance, Consulting, Professional Services, Luxury, Retail, Residential Building & Real Estate, Community, Intel, EBay, Apple, Netflix, IPA, Air conditioning, Sale, Acquisition, MMI, Marcus & Millichap, Silicon, Samsung, Cisco, Adobe, State, PayPal

Institutional Property Advisors (IPA) , a division of Marcus & Millichap (NYSE: MMI) , announced today the sale of Prado, a 251-unit multifamily asset in Santa Clara, California.

Key Points: 
  • Institutional Property Advisors (IPA) , a division of Marcus & Millichap (NYSE: MMI) , announced today the sale of Prado, a 251-unit multifamily asset in Santa Clara, California.
  • The property traded for $125 million, or $498,008 per unit.
  • IPA Capital Markets arranged $73.5 million in acquisition financing.
  • “Investor demand for quality assets in supply-constrained markets is on the rise, as demonstrated by high engagement levels on listing assignments.